Kairos Pharma to Host Key Opinion Leader Event on Phase 2 Prostate Cancer Trial Results

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced it will host a key opinion leader event on September 18, 2025, at 5 p.m. ET to discuss interim efficacy results from its Phase 2 trial of lead candidate ENV105 in advanced prostate cancer. The event will feature safety and efficacy findings from the ENV105 and apalutamide combination therapy, with expert perspectives highlighting the compound's potential role in addressing cancer drug resistance.

ENV105 represents a novel approach to overcoming one of the most significant challenges in cancer treatment: drug resistance. The antibody targets CD105, a protein identified as a key driver of resistance to various cancer treatments. According to company information, elevation of CD105 in response to standard therapy results in resistance and disease relapse, making ENV105's mechanism of action particularly relevant for patients who have developed resistance to existing treatments.

The Phase 2 clinical trial focuses on castrate-resistant prostate cancer, a condition with significant unmet medical needs where patients often exhaust available treatment options. The company also has ENV105 in a Phase 1 trial for lung cancer, indicating broader potential applications across multiple cancer types. The upcoming KOL event will provide crucial insights into whether ENV105 can effectively reverse drug resistance and restore the effectiveness of standard therapies.

For investors and stakeholders seeking additional information, the latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA. The full press release containing the announcement can be viewed at https://ibn.fm/DrvAm. The event's outcomes could have significant implications for prostate cancer treatment paradigms and the broader oncology therapeutic landscape.